menu
    • menu
    [{"orgOrder":0,"company":"Blackstone Life Sciences","sponsor":"Alnylam Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"Inclisiran","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Blackstone Life Sciences","amount2":2,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":2,"dosageForm":"","sponsorNew":"Blackstone Life Sciences \/ Blackstone","highestDevelopmentStatusID":"10","companyTruncated":"Blackstone Life Sciences \/ Blackstone"},{"orgOrder":0,"company":"Blackstone Life Sciences","sponsor":"Reata Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Financing","leadProduct":"Bardoxolone Methyl","moa":"Nrf2","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Blackstone Life Sciences","amount2":0.34999999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.34999999999999998,"dosageForm":"Capsule","sponsorNew":"Blackstone Life Sciences \/ Blackstone","highestDevelopmentStatusID":"10","companyTruncated":"Blackstone Life Sciences \/ Blackstone"},{"orgOrder":0,"company":"Blackstone Life Sciences","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Small molecule","year":"2020","type":"Divestment","leadProduct":"Fursultiamine","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Blackstone Life Sciences","amount2":2.2999999999999998,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":2.2999999999999998,"dosageForm":"Tablet","sponsorNew":"Blackstone Life Sciences \/ Blackstone Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Blackstone Life Sciences \/ Blackstone Therapeutics"},{"orgOrder":0,"company":"Blackstone Life Sciences","sponsor":"Alnylam Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Financing","leadProduct":"Vutrisiran","moa":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Blackstone Life Sciences","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.14999999999999999,"dosageForm":"Subcutaneous Injection","sponsorNew":"Blackstone Life Sciences \/ Blackstone Life Sciences","highestDevelopmentStatusID":"10","companyTruncated":"Blackstone Life Sciences \/ Blackstone Life Sciences"},{"orgOrder":0,"company":"Blackstone Life Sciences","sponsor":"Medtronic Plc","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Funding","leadProduct":"Insulin","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Blackstone Life Sciences","amount2":0.34000000000000002,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0.34000000000000002,"dosageForm":"Capsule","sponsorNew":"Blackstone Life Sciences \/ Blackstone Life Sciences","highestDevelopmentStatusID":"12","companyTruncated":"Blackstone Life Sciences \/ Blackstone Life Sciences"},{"orgOrder":0,"company":"Blackstone Life Sciences","sponsor":"Autolus Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2021","type":"Acquisition","leadProduct":"Obecabtagene Autoleucel","moa":"CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Blackstone Life Sciences","amount2":0.25,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.25,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Blackstone Life Sciences \/ Blackstone Life Sciences","highestDevelopmentStatusID":"7","companyTruncated":"Blackstone Life Sciences \/ Blackstone Life Sciences"},{"orgOrder":0,"company":"Blackstone Life Sciences","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"Dexamethasone","moa":"CD38","graph1":"Oncology","graph2":"Approved","graph3":"Blackstone Life Sciences","amount2":0.33000000000000002,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0.33000000000000002,"dosageForm":"Subcutaneous Solution","sponsorNew":"Blackstone Life Sciences \/ Blackstone","highestDevelopmentStatusID":"12","companyTruncated":"Blackstone Life Sciences \/ Blackstone"},{"orgOrder":0,"company":"Blackstone Life Sciences","sponsor":"Ferring Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"Nadofaragene Firadonavec","moa":"INF alpha 2b","graph1":"Oncology","graph2":"Phase III","graph3":"Blackstone Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Blackstone Life Sciences \/ Blackstone Life Sciences","highestDevelopmentStatusID":"10","companyTruncated":"Blackstone Life Sciences \/ Blackstone Life Sciences"},{"orgOrder":0,"company":"Blackstone Life Sciences","sponsor":"PTC Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Ataluren","moa":"CFTR","graph1":"Genetic Disease","graph2":"Approved","graph3":"Blackstone Life Sciences","amount2":0.050000000000000003,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0.050000000000000003,"dosageForm":"Granules for Oral Suspension","sponsorNew":"Blackstone Life Sciences \/ Blackstone Life Sciences","highestDevelopmentStatusID":"12","companyTruncated":"Blackstone Life Sciences \/ Blackstone Life Sciences"},{"orgOrder":0,"company":"Blackstone Life Sciences","sponsor":"Sutro Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Collaboration","leadProduct":"24-valent Pneumococcal Conjugate Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Blackstone Life Sciences","amount2":0.39000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.39000000000000001,"dosageForm":"Injectable\/Injection","sponsorNew":"Blackstone Life Sciences \/ Blackstone Life Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Blackstone Life Sciences \/ Blackstone Life Sciences"},{"orgOrder":0,"company":"Blackstone Life Sciences","sponsor":"Amicus Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Financing","leadProduct":"Migalastat","moa":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Blackstone Life Sciences","amount2":0.029999999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0.029999999999999999,"dosageForm":"Capsule","sponsorNew":"Blackstone Life Sciences \/ Blackstone Life Sciences","highestDevelopmentStatusID":"12","companyTruncated":"Blackstone Life Sciences \/ Blackstone Life Sciences"},{"orgOrder":0,"company":"Blackstone Life Sciences","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Financing","leadProduct":"mRNA-1010","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Blackstone Life Sciences","amount2":0.75,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.75,"dosageForm":"Injection","sponsorNew":"Blackstone Life Sciences \/ Blackstone Life Sciences","highestDevelopmentStatusID":"10","companyTruncated":"Blackstone Life Sciences \/ Blackstone Life Sciences"},{"orgOrder":0,"company":"Blackstone Life Sciences","sponsor":"Uniquity Bio","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Financing","leadProduct":"Solrikitug","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Blackstone Life Sciences","amount2":0.29999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.29999999999999999,"dosageForm":"","sponsorNew":"Blackstone Life Sciences \/ Blackstone Life Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Blackstone Life Sciences \/ Blackstone Life Sciences"},{"orgOrder":0,"company":"Blackstone Life Sciences","sponsor":"Uniquity Bio","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Solrikitug","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Blackstone Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Blackstone Life Sciences \/ Blackstone Life Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Blackstone Life Sciences \/ Blackstone Life Sciences"}]

    Find Clinical Drug Pipeline Developments & Deals by Blackstone Life Sciences

    Menu

    Blackstone Life Sciences

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Blackstone Life Sciences

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Blackstone Life Sciences

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Solrikitug

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase I

                            Recipient : Uniquity Bio

                            Deal Size : $300.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Blackstone Unsheathes Uniquity Bio with $300M

                            Details : The financing aims to fund the clinical development of MK-8226 (solrikitug), which is being evaluated in the early-stage clinical trial for chronic obstructive pulmonary disease and asthma.

                            Brand Name : MK-8226

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            May 15, 2024

                            Lead Product(s) : Solrikitug

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase I

                            Recipient : Uniquity Bio

                            Deal Size : $300.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Blackstone Life Sciences

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Blackstone Life Sciences

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Solrikitug

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase I

                            Recipient : Uniquity Bio

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Blackstone Launches Uniquity Bio For Novel Immunology And Inflammation Medicines

                            Details : MK-8226 (solrikitug), is a highly potent anti-TSLP monoclonal antibody, which is being evaluated in early-stage clinical trial for the treatment of chronic obstructive pulmonary disease and asthma.

                            Brand Name : MK-8226

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            May 15, 2024

                            Lead Product(s) : Solrikitug

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase I

                            Recipient : Uniquity Bio

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Blackstone Life Sciences

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Blackstone Life Sciences

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : mRNA-1010

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Recipient : Moderna Therapeutics

                            Deal Size : $750.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Blackstone Life Sciences Announces Collaboration to Support Moderna’s Influenza Program

                            Details : Proceeds will fund Moderna's influenza program, including mRNA-1010, a quadrivalent flu vaccine encoding hemagglutinin (HA) glycoproteins for four strains, administered intramuscularly.

                            Brand Name : mRNA-1010

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            March 27, 2024

                            Lead Product(s) : mRNA-1010

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Recipient : Moderna Therapeutics

                            Deal Size : $750.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Blackstone Life Sciences

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Blackstone Life Sciences

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Migalastat

                            Therapeutic Area : Genetic Disease

                            Study Phase : Approved

                            Recipient : Amicus Therapeutics

                            Deal Size : $30.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Amicus Therapeutics and Blackstone Enter into $430 Million Strategic Financing Collaboration

                            Details : The proceeds will be used to fund the ongoing operations of the company, including Galafold (migalastat), a small molecule and the first and only oral therapy for adults with Fabry disease and an amenable GLA variant.

                            Brand Name : Galafold

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            October 02, 2023

                            Lead Product(s) : Migalastat

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Approved

                            Recipient : Amicus Therapeutics

                            Deal Size : $30.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Blackstone Life Sciences

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Blackstone Life Sciences

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 24-valent Pneumococcal Conjugate Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Recipient : Sutro Biopharma

                            Deal Size : $390.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Sutro Biopharma and Blackstone Announce Royalty Financing Collaboration

                            Details : The financing will be used for the continued pipeline advancement and further development of its cell-free protein synthesis and site-specific conjugation technologies, including VAX-24, a Phase 3 ready, 24-valent next-generation pneumococcal conjugate v...

                            Brand Name : VAX-24

                            Molecule Type : Vaccine

                            Upfront Cash : $140.0 million

                            June 26, 2023

                            Lead Product(s) : 24-valent Pneumococcal Conjugate Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Recipient : Sutro Biopharma

                            Deal Size : $390.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Blackstone Life Sciences

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Blackstone Life Sciences

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ataluren

                            Therapeutic Area : Genetic Disease

                            Study Phase : Approved

                            Recipient : PTC Therapeutics

                            Deal Size : $50.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            PTC Therapeutics Announces Strategic Financing Collaboration with Blackstone with up to $1 Billion in Funding

                            Details : The strategic financing will support the acceleration of PTC’s robust and diversified pipeline having lead asset Translarna (ataluren), business development opportunities and general corporate purposes.

                            Brand Name : Translarna

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            October 27, 2022

                            Lead Product(s) : Ataluren

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Approved

                            Recipient : PTC Therapeutics

                            Deal Size : $50.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Blackstone Life Sciences

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Blackstone Life Sciences

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nadofaragene Firadonavec

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Recipient : Ferring Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Ferring Pharmaceuticals and Blackstone Life Sciences Restructure Novel Gene Therapy Collaboration

                            Details : The restructured agreement allows for a return on capital already invested by Blackstone, and also provides Blackstone with option to make a passive financial investment in nadofaragene firadonavec (rAd-IFN/Syn3) upon achievement of a specified regulator...

                            Brand Name : rAd-IFN/Syn3

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            October 17, 2022

                            Lead Product(s) : Nadofaragene Firadonavec

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Recipient : Ferring Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Blackstone Life Sciences

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Blackstone Life Sciences

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Isatuximab,Pomalidomide,Dexamethasone

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Sanofi

                            Deal Size : $330.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Sanofi Announces €300 Million Collaboration with Blackstone Life Sciences to Advance an Innovative Treatment...

                            Details : For the Sarclisa® subcutaneous formulation delivery, Sanofi has partnered with drug delivery technology innovator company to advance the development of a subcutaneous delivery for Sarclisa® with the goal of offering a unique patient-centric treatment e...

                            Brand Name : Sarclisa

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            March 15, 2022

                            Lead Product(s) : Isatuximab,Pomalidomide,Dexamethasone

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Sanofi

                            Deal Size : $330.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Blackstone Life Sciences

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Blackstone Life Sciences

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Obecabtagene Autoleucel

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Recipient : Autolus Therapeutics

                            Deal Size : $250.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Blackstone Life Sciences to Invest up to $250 Million in Autolus Therapeutics to Develop Obe-cel in Adult Acut...

                            Details : Obecabtagene Autoleucel (Obe-cel) is a CD19 CAR T cell investigational therapy designed to overcome the limitations in clinical activity and safety compared to current CD19 CAR T cell therapies used in adult ALL and B-NHL.

                            Brand Name : Obe-cel

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            November 08, 2021

                            Lead Product(s) : Obecabtagene Autoleucel

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : Autolus Therapeutics

                            Deal Size : $250.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Blackstone Life Sciences

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Blackstone Life Sciences

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fursultiamine

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved

                            Recipient : Takeda Pharmaceutical

                            Deal Size : $2,300.0 million

                            Deal Type : Divestment

                            DEALS_DEV arrow-down

                            Takeda to Divest its Japan Consumer Health Care Business Unit to Blackstone for JPY 242.0 Billion

                            Details : The portfolio to be divested includes a variety of over-the-counter medicines and health products. TCHC’s strong regional brands include Alinamin, and Benza.

                            Brand Name : Alinamin

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            August 24, 2020

                            Lead Product(s) : Fursultiamine

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved

                            Recipient : Takeda Pharmaceutical

                            Deal Size : $2,300.0 million

                            Deal Type : Divestment

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth